![Epic Sciences said today its liquid biopsy blood test showed in a study that it can help physicians select prostate cancer patients who are likely to benefit from a Pfizer prostate-specific membrane antigen (PSMA)-targeted therapy candidate known as BIND-014 before the start of treatment. [Source: © Alex Tihonov/Fotolia]](https://www.insideprecisionmedicine.com/wp-content/uploads/2019/01/1907-218x150.jpeg "LAM Gets FDA Breakthrough Designation for Liver Cancer Liquid Biopsy")
LAM Gets FDA Breakthrough Designation for Liver Cancer Liquid Biopsy
Bringing it closer to one of the world’s fastest-growing diagnostic market places, the Laboratory for Advanced Medicine (LAM)’s blood-based liver cancer test has been...
Cell-Free DNA Used for Infectious Disease Testing
In recent years we’ve seen the power of analyzing cell-free DNA to diagnose and track the progression of cancer. Yet, using this technology as...
Clinical NGS IDs Pathogens in Brain and Spinal Fluid Missed by Other Tests
Doctors were able to give critically ill patients with mysterious neurological symptoms life-saving treatment thanks to a new clinical application of next-generation sequencing (NGS)....
Proteogenomic Colon Cancer Analysis Offers New Diagnostic, Therapeutic Insights
Colon cancer ranks third in prevalence and fourth in cancer deaths among all cancers worldwide. However, due to its extreme heterogeneity, progress has been slow towards precision diagnostics and treatments.
Concerto HealthAI Enters Precision Oncology Collaboration with Pfizer
Concerto HealthAI announced today the company entered a precision oncology collaboration with Pfizer using Concerto HealthAI’s eurekaHealth platform, artificial intelligence (AI) models and data...
Caris IDs potential Non-Hodgkins Lymphoma Drug Target
Molecular biology company Caris Life Sciences has published new data in Cell Chemical Biology that could offer a new pathway to the treatment of...
ArcherDx, UCL Collaborate on ctDNA Lung Cancer Study
The collaboration with the University College London (UCL) and the Francis Crick Institute will use ArcherDX's proprietary Anchored Multiplex PCR (AMP) technology to detect evidence of disease recurrence in lung cancer patients using cell-free circulating tumor DNA (ctDNA) as part of the UCL-sponsored TRACERx clinical study.
Lloyd Sanders Named New CEO of Epic Sciences
Sanders comes to Epic from Myriad Genetics where he served as president of the company’s oncology segment.
